

Rachna T Shroff

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7212637/publications.pdf>

Version: 2024-02-01

75
papers

6,948
citations

136740

32
h-index

91712

69
g-index

76
all docs

76
docs citations

76
times ranked

7815
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel biomarkers and the future of targeted therapies in cholangiocarcinoma: a narrative review. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 253-266.	0.7	8
2	The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. <i>Hepatology</i> , 2022, 75, 297-308.	3.6	32
3	Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH1-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors. <i>JCO Precision Oncology</i> , 2022, 6, e2100197.	1.5	10
4	Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis. <i>European Journal of Cancer</i> , 2022, 172, 65-75.	1.3	24
5	Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures. <i>JCO Precision Oncology</i> , 2022, , .	1.5	19
6	Precision Medicine in Biliary Tract Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 2716-2734.	0.8	12
7	The impact of molecular profiling on cholangiocarcinoma clinical trials and experimental drugs. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 281-284.	1.9	7
8	Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2268-2274.	0.6	0
9	Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation. <i>JAMA Oncology</i> , 2021, 7, 1669.	3.4	194
10	Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. <i>Nature Medicine</i> , 2021, 27, 2002-2011.	15.2	167
11	Current and emerging therapies for advanced biliary tract cancers. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 956-969.	3.7	81
12	Moving the Needle Forward With Locoregional Treatment in Unresectable Cholangiocarcinoma—The Jury Is Still Out. <i>JAMA Oncology</i> , 2020, 6, 29.	3.4	7
13	Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1385-1394.	3.2	31
14	Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 4317-4345.	0.8	350
15	What is the role of PARP inhibitors in pancreatic cancer?. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 913-918.	1.1	3
16	Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 796-807.	5.1	620
17	Moving Beyond Chemotherapy for Pancreaticobiliary Tumors: Targeted and Immunotherapy Strategies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, , e333-e343.	1.8	1
18	Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. <i>Cancer Medicine</i> , 2020, 9, 5406-5415.	1.3	9

#	ARTICLE	IF	CITATIONS
19	Dose-modified gemcitabine plus nab-paclitaxel front-line in advanced pancreatic ductal adenocarcinoma with baseline hyperbilirubinemia. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 55-60.	0.6	5
20	Pancreatic cancer. <i>Lancet, The</i> , 2020, 395, 2008-2020.	6.3	1,376
21	Infigratinib in patients with advanced cholangiocarcinoma with <i>FGFR2</i> gene fusions/translocations: the PROOF 301 trial. <i>Future Oncology</i> , 2020, 16, 2375-2384.	1.1	62
22	Biliary tract cancers: systemic therapy for advanced disease. <i>Chinese Clinical Oncology</i> , 2020, 9, 5-5.	0.4	7
23	Charging forward in locally advanced pancreatic cancer. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 234-236.	3.7	3
24	Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. <i>Pancreatology</i> , 2020, 20, 501-504.	0.5	31
25	Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers. <i>World Journal of Gastrointestinal Oncology</i> , 2020, 12, 83-91.	0.8	1
26	Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 711-720.	3.7	161
27	Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers. <i>JAMA Oncology</i> , 2019, 5, 824.	3.4	335
28	Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2019, 37, 1015-1027.	0.8	301
29	First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 619-627.	0.7	8
30	Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4087-4087.	0.8	42
31	Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 866-876.	0.8	13
32	Emerging Targeted and Immunotherapies in Cholangiocarcinoma. <i>Oncology & Hematology Review</i> , 2019, 15, 71.	0.2	1
33	Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater. <i>Oncologist</i> , 2018, 23, 277-e26.	1.9	34
34	Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 337-348.	3.7	189
35	A Case Report—Stevens-Johnson Syndrome as an Adverse Effect of Capecitabine. <i>Journal of Gastrointestinal Cancer</i> , 2018, 49, 349-350.	0.6	6
36	Cholangiocarcinoma With <i>FGFR</i> Genetic Aberrations: A Unique Clinical Phenotype. <i>JCO Precision Oncology</i> , 2018, 2, 1-12.	1.5	86

#	ARTICLE	IF	CITATIONS
37	Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 276-282.	0.8	524
38	Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. <i>Cancer Medicine</i> , 2018, 7, 4880-4892.	1.3	23
39	Tu1402 COMPARISON OF THE PERFORMANCE OF COVERED METAL STENTS AND UNCOVERED METAL STENTS IN THE MANAGEMENT OF MALIGNANT BILIARY STRICTURES (MBO) IN 1012 PATIENTS.. <i>Gastrointestinal Endoscopy</i> , 2018, 87, AB580.	0.5	0
40	Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. <i>Journal of Hematology and Oncology</i> , 2018, 11, 71.	6.9	30
41	A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 5883-5894.	3.2	76
42	The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma. <i>British Journal of Cancer</i> , 2017, 116, 1402-1407.	2.9	54
43	Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study. <i>Oncologist</i> , 2017, 22, 804-810.	1.9	91
44	Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: A comprehensive analysis of 362 consecutive patients. <i>Cancer</i> , 2017, 123, 1354-1362.	2.0	37
45	Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. <i>JAMA Surgery</i> , 2017, 152, 1048.	2.2	82
46	Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. <i>Annals of Surgical Oncology</i> , 2017, 24, 2031-2039.	0.7	30
47	Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study. <i>Cancer</i> , 2017, 123, 1011-1017.	2.0	45
48	Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 164-174.	0.9	124
49	Systemic therapy for unresectable, mixed hepatocellular-cholangiocarcinoma: treatment of a rare malignancy. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 347-351.	0.6	30
50	Precision medicine for gallbladder cancer using somatic copy number amplifications (SCNA) and DNA repair pathway gene alterations.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4076-4076.	0.8	8
51	Tumor mutational burden (TMB) and co-existing actionable mutations in biliary tract cancers (BTC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4086-4086.	0.8	8
52	Preliminary safety data from a randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4125-4125.	0.8	10
53	Clinical features and tumor mutational profile of younger versus older patients with cholangiocarcinoma (CCA).. <i>Journal of Clinical Oncology</i> , 2017, 35, 240-240.	0.8	0
54	Early obesity and risk of cholangiocarcinoma in the United States.. <i>Journal of Clinical Oncology</i> , 2017, 35, 239-239.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Phase II study of panitumumab in KRAS wild-type metastatic adenocarcinoma of the small bowel or ampulla of vater.. Journal of Clinical Oncology, 2017, 35, e15799-e15799.	0.8	1
56	Simultaneous molecular alterations in solid tumors with IDH1 or IDH2 mutations.. Journal of Clinical Oncology, 2017, 35, 11609-11609.	0.8	0
57	Characterization of germline genomic alterations in familial pancreas cancer.. Journal of Clinical Oncology, 2017, 35, 4116-4116.	0.8	2
58	Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget, 2016, 7, 67495-67506.	0.8	42
59	BRCA-associated protein 1 mutant cholangiocarcinoma: an aggressive disease subtype. Journal of Gastrointestinal Oncology, 2016, 7, 556-561.	0.6	20
60	Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer, 2016, 122, 2671-2679.	2.0	49
61	Nextâ€generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance. Cancer, 2016, 122, 3657-3666.	2.0	41
62	Biliary cancer: Utility of nextâ€generation sequencing for clinical management. Cancer, 2016, 122, 3838-3847.	2.0	289
63	Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. Journal of Gastrointestinal Surgery, 2016, 20, 1975-1985.	0.9	42
64	Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. Journal of Clinical Oncology, 2016, 34, 219-226.	0.8	242
65	Consensus Conference on Gallbladder Cancer. Hpb, 2015, 17, 664-665.	0.1	5
66	The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy. Annals of Surgical Oncology, 2015, 22, 1221-1228.	0.7	44
67	HER2/neu-directed therapy for biliary tract cancer. Journal of Hematology and Oncology, 2015, 8, 58.	6.9	191
68	Adjuvant/Perioperative Therapy in Pancreatic and Periapillary Cancer. Indian Journal of Surgery, 2015, 77, 403-408.	0.2	2
69	Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2015, 76, 489-498.	1.1	59
70	Underuse of surgical resection among elderly patients with early-stage pancreatic cancer. Surgery, 2015, 158, 1226-1234.	1.0	31
71	Does IGF1R inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?. Journal of Cachexia, Sarcopenia and Muscle, 2014, 5, 307-313.	2.9	21
72	Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications. PLoS ONE, 2014, 9, e115383.	1.1	362

#	ARTICLE	IF	CITATIONS
73	Second-line systemic treatment for advanced cholangiocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, 408-13.	0.6	34
74	The Expression of PTEN Is Associated With Improved Prognosis in Patients With Ampullary Adenocarcinoma After Pancreaticoduodenectomy. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 1619-1626.	1.2	14
75	Randomized Controlled Trial Of Dalteparin For Primary Thromboprophylaxis For Venous Thromboembolism (VTE) In Patients With Advanced Pancreatic Cancer (APC): Risk Factors Predictive Of VTE. <i>Blood</i> , 2013, 122, 580-580.	0.6	27